Duncan Jason bought ENGN
November 13, 2026 · Form 4 insider transaction
Duncan Jason bought 500,000 shares of enGene Therapeutics Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 0 days after the transaction.
Direction
Acquired (buy-side)
Shares
500,000
Price
$0.00
Total value
N/A
InsiderDuncan Jason
RoleOfficer
SecurityStock Option (Right to Buy)
Transaction codeA: Grant or award
Transaction dateNovember 13, 2026
Filing dateNovember 13, 2026
Shares owned after500,000
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The stock options vest as to 25% of the total number of shares on the first anniversary of November 13, 2026, and the remainder vesting and becoming exercisable in substantially equal amounts monthly for three years thereafter, subject to the reporting person's continued service.